Modulating Inflammation in Neuro-Trauma
Key facts
- Who runs it
- The University of Texas Health Science Center at San Antonio
- Where
- San Antonio, United StatesSee the 2 sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 16 people, planned
- Started
- Nov 2026
- Expected to end
- Jul 2027
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Nurosym taVNS
- Nurosym (sham)
- Record updated
- 5 October 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age 18-75 years old
- Glasgow Coma Scale (GCS) Score 3-12
- Expected Intensive Care Unit (ICU) stay > 48 hours
- Presenting with acute Traumatic Brain Injury (TBI) within 24 hours
Who cannot take part
- Immunomodulatory medication
- Human Immune Deficiency Virus (HIV) patients
- Autoimmune disease
- Known cancer immunotherapy
- Past medical history of symptomatic bradycardia
- Pregnant
- Any electrical implanted device
- Penetrating brain injury
- Clinical team assessment of prognosis and imminent risk of death such as Decision to withdraw life-sustaining measures
- Current incarceration
- Trauma/Laceration to the left ear
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- University HospitalSan Antonio, United StatesContact: Patrick ThompsonNot yet recruiting
- University of Texas Health Science Center at San AntonioSan Antonio, United StatesContact: Patrick ThompsonNot yet recruiting
About the trial
What the trial wants to find out
MINT is a single-site, prospective, randomized, double-blind, sham-controlled pilot trial evaluating the safety and feasibility of transcutaneous auricular vagus nerve stimulation (taVNS) in patients with moderate to severe traumatic brain injury (GCS 3-12). Participants will be randomized to receive either active taVNS or sham stimulation using the same device. The primary objective is to assess the safety and feasibility of taVNS implementation in the acute TBI setting. Secondary objectives include exploratory measurement of serum inflammatory and neuronal injury biomarkers and assessment of functional outcome using the Extended Glasgow Outcome Scale at hospital discharge.
The 2 groups in the trial
- Treatment group taVNSTreatment being tested
Treatment with transauricular vagus nerve stimulation (taVNS) after admission to trauma with a traumatic brain injury (TBI)
Treatment: Nurosym taVNS
- Control groupSham treatment, for comparison
The control group will undergo sham stimulation using the same device placed at the same location with a brief, low level stimulation that tapers over 30 seconds.
Treatment: Nurosym (sham)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- MINT: Modulating Inflammation in Neuro-Trauma
- Criteria questions
- Built from NCT07510074, who can take part
- Record updated
- 5 October 2026